Company achieved significant commercial progress in 2023
IBSRELA® now expected to generate greater than $1.0 billion in annual U.S. net product sales revenue at peak
Webcast scheduled for 7:00 PM ET / 4:00 PM PT to discuss IBS-C Market
Webcast Details
The company will host a live event and webcast today, January 8, 2024, at 7:00 p.m. ET / 4:00 p.m. PT. The event will include a management update on IBSRELA, the company’s FDA approved treatment for irritable bowel syndrome with constipation (IBS-C), as well as a Key Opinion Leader discussion regarding the IBS-C treatment landscape with Philip Schoenfeld, MD, MS Ed, MSc, Chief (Emeritus) of the Gastroenterology Section at the John D. Dingell VA Medical Center in Detroit, Mich. The webcast can be accessed by visiting the Investor page of the company's website, www.ardelyx.com, and will be available on the website for at least 30 days following the call.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.